CVAC - CureVac Corp Year-over-year net earnings per share growth for the last 12 months

AI-platform automation of mRNA synthesis accelerates development but creates volatility, as demonstrated by the quarterly EPS dynamics. The -14.20 level captures the latest values of this trend. CureVac N.V. (CVAC) relies on a costly cold chain for drug delivery to maintain business stability, while its financial resilience is based on partner grants and the terms of major pharmaceutical contracts.

curevac.com (CVAC) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 01/17/2026

CVAC (CureVac Pharma): analytical breakdowns and indicator data

- market value and analyst target forecast:

Price Chart CureVac|CVAC - Fair Value Consensus

- market capitalization statistics:

Market Valuation CureVac Corp|CVAC - Enterprise Value

- book capitalization indicators:

Net Assets per Single Share CureVac|CVAC - Book Valuation of Business|Market Capitalization to Book Value Ratio curevac.com|CVAC - Cumulative Company Assets

- debt and liquidity data:

- earnings and market multiples details:

CVAC - Net Profit|Projected Future Earnings CureVac N.V.|CVAC - Price to Earnings Ratio|Projected Price to Earnings CureVac Corp|CVAC - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CureVac Corp|CVAC - Operating profit before amortization|Net earnings per share for the last 12 months CureVac|CVAC - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months curevac.com|CVAC - Earnings per share growth in current year|Expected earnings per share growth for next year CureVac N.V.

- sales and revenue data:

CVAC - Company Gross Revenue|Projected Sales Volume CureVac|CVAC - Market Cap to Revenue|Forward Price-to-Revenue Multiple CureVac Corp

Summary company analytics:CureVac - CVAC

Quarterly EPS growth reflects the dynamics of net income per share and serves as a key indicator of capital efficiency. By analyzing the current quarterly EPS trend, an investor assesses the rate of change in business profitability. This metric is calculated as the percentage deviation of current period earnings from the same quarter of the previous year. For CureVac N.V. (CVAC), this indicator marks a transition to an autonomous development cycle. Amid patent disputes and a strategic shift toward cancer vaccines, EPS demonstrates financial resilience during structural reorganization.

Analysis of competing companies

Gilead Sciences (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara Corp - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth Valneva Vaccines|Year-over-year earnings per share growth for the last twelve months Vir Biotechnology, Inc. (VIR)|Year-over-year net earnings per share change for the last twelve months siga.com|Quarterly EPS earnings growth EBS (Emergent BioSolutions Inc.)|AVIR - Year-over-year net earnings per share growth for the last 12 months|IVVD: Year-over-year net earnings per share growth for the last 12 months|ENTA - Quarterly EPS earnings growth|Inovio Pharmaceuticals (INO) - Year-over-year earnings per share growth for the last twelve months|hillevax.com - Year-over-year earnings per one share growth for the last 12 months|KLRS (Kalaris Therapeutics) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Dyadic DYAI|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides, Inc.)|Year-over-year earnings per share growth for the last twelve months TLPH (Talphera Corporation)|Quarterly EPS earnings growth COCP (Cocrystal Pharma, Inc.)|Quarterly EPS earnings growth Traws Pharma Inc TRAW|Virios Therapeutics - Quarterly EPS earnings growth|Qualigen Therapeutics Inc (QLGN) - Year-over-year net earnings per share growth for the last 12 months|ALVR (allovir.com) - Year-over-year net earnings per share growth for the last 12 months|VBI Vaccines - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Virios Therapeutics Inc.|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart Corp)